Archive ready
医薬品医療機器等法に基づく新型コロナウイルス感染症に係る治療薬の承認について｜厚生労働省
https://www.mhlw.go.jp/stf/newpage_18199.htmlApril 9, 2026 at 03:02 AM JST•The archive page, viewer, and downloads use this saved version.
April 9, 2026 at 03:02 AM JST·www.mhlw.go.jp
The evidence pack includes HTML, screenshots, summaries, and metadata. It can be downloaded on Pro.
Saved page
医薬品医療機器等法に基づく新型コロナウイルス感染症に係る治療薬の承認について｜厚生労働省
Open the archived HTML with saved-time metadata attached.
Original URLhttps://www.mhlw.go.jp/stf/newpage_18199.html
StartedApril 9, 2026 at 03:02 AM JST
This HTML has CSS and images embedded, so it can still be opened even if the original page disappears.
About this pageAI generated
This page is a press release from Japan's Ministry of Health, Labour and Welfare dated April 23, 2021, announcing the approval of Olumiant tablets as a COVID-19 treatment. The active ingredient is baricitinib, a JAK inhibitor. It is approved for pneumonia patients requiring oxygen therapy, administered orally at 4mg once daily in combination with remdesivir. The application was filed by Eli Lilly Japan K.K. on December 25, 2020.
